8.95
0.27 (3.11%)
| Previous Close | 8.68 |
| Volume | 171,085 |
| Price / Sales | 5.46 |
| Price / Book | 8.86 |
| 52 Weeks Range |
| Profit Margin | -63.24% |
| Operating Margin (TTM) | -79.16% |
| Diluted EPS (TTM) | -0.980 |
| Quarterly Revenue Growth (YOY) | -9.10% |
| Total Debt/Equity (MRQ) | 52.12% |
| Current Ratio (MRQ) | 10.47 |
| Operating Cash Flow (TTM) | -24.17 M |
| Levered Free Cash Flow (TTM) | -8.84 M |
| Return on Assets (TTM) | -21.77% |
| Return on Equity (TTM) | -52.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Sight Sciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.83 |
|
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 20.87% |
| % Held by Institutions | 50.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kck Ltd. | 30 Sep 2025 | 4,374,975 |
| Americana Partners, Llc | 30 Jun 2026 | 1,679,069 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |